-
Uncategorized3 weeks agoRevolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a...
-
AI, Machine Learning & Computational Biology3 weeks agoSpyre tumbles as immune drug misses mark in rheumatoid arthritis
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
-
Uncategorized3 weeks ago
Research into protein interactions sheds new light on causes of autism
Studying protein-protein interactions might hold the key to identifying druggable targets for autism, a group of scientists at the University of California, San Francisco has suggested.
-
Uncategorized3 weeks ago
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
The Phase 3 readout is the first for ivonescimab beyond non-small cell lung cancer to show a significant overall survival benefit, according to Summit Therapeutics and...
-
Uncategorized3 weeks ago
BMS ends Cellares pact over cell therapy production problems, triggering layoffs
Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its partnership with the manufacturing specialist.
-
Uncategorized3 weeks ago
Biohaven could get up to $795M in epilepsy alliance with SK Bio
At the center of Biohaven’s agreement with SK Biopharmaceutical is the ion channel platform and the lead epilepsy candidate opakalim, for which Phase 2/3 data are...
-
Uncategorized3 weeks ago
Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.
-
Uncategorized3 weeks agoWeight-loss pill may quiet alcohol cravings
New research has shown that people taking oral semaglutide – the active ingredient used in Wegovy – experienced fewer heavy-drinking days, consumed fewer drinks when they...
-
Uncategorized3 weeks ago
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
FDA extends its review of Capricor Therapeutics’ Duchenne muscular dystrophy cell therapy as an unhappy shareholder advocates for change; Merck and Moderna tout positive data for...
-
Uncategorized3 weeks ago
CDMO hiring tough as demand for specialized talent outpaces supply
The talent pool not keeping pace with increased outsourcing demand is just one reason CDMOs have trouble filling roles, according to a search expert. He also...
FDA clears first generic radioligand drug; Sionna turns to layoffs
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
Ensuring safety and accountability in China’s biomedical translation system
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
